David M. Parham

High Impact

Role not yet determined Is this you? Add your title

UAMS primary UA Little Rock

Also affiliated: Northwestern University (2014); University of Nebraska–Lincoln (1999); University of Southern California (2010–2024); University of Nebraska at Omaha (2010); Western University (2024); Baptist Memorial Hospital (1989–1999); Boston Children's Hospital (2015–2022); Roswell Park Comprehensive Cancer Center (1999); Lurie Children's Hospital (2014); Seattle Children's Hospital (2007–2018); Children's Medical Center (2023); National Institutes of Health (1999–2013); Arkansas Children's Hospital (1997–2008); University of Minnesota (2002–2015); Nebraska Medical Center (2011–2015); St. Jude Children's Research Hospital (1982–2014); Nationwide Children's Hospital (2003–2014); Mount Sinai Hospital (1982); Mayo Clinic (1999–2018); Boehringer Ingelheim (Germany) (2018); Memorial Sloan Kettering Cancer Center (1982–2000); Children's Hospital of Los Angeles (2013–2025); The University of Texas MD Anderson Cancer Center (2011–2018); Pediatric Oncology Group (1994); Johns Hopkins University (2007); Emory University (2000); University of Tennessee Health Science Center (1977–2013); University of Pittsburgh (2009–2011); University of Dundee (1988–1993); Baylor College of Medicine (2007); King Abdulaziz University (2024); East Carolina University (2015); University of Washington (2013–2015); University of South Florida (2010); Royal Bournemouth Hospital (1994–2016); Keck Hospital of USC (2018); Perth Royal Infirmary (1992); Inova Fairfax Hospital (2003); Hospital for Sick Children (2002); Ninewells Hospital (1988–2008); Tianjin Medical University Cancer Institute and Hospital (2024); Edinburgh Royal Infirmary (1985); University Hospital Southampton NHS Foundation Trust (2023–2025); University of Oklahoma Medical Center (2010–2011); Elekta (Switzerland) (2018); Yale University (1991); University of Florida (1999–2018); University of Chicago Medical Center (2011); Fred Hutch Cancer Center (2013–2015); Dell Children's Medical Center of Central Texas (2011); Children's Hospital of Oklahoma (2008); Inova Children's Hospital (2003); Maine Medical Center (2013); Duke Medical Center (2007); Children's Hospital of Pittsburgh (2007–2011); Children's Oncology Group (2003–2013); Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (1996–2010); Stanford Medicine (2002–2011); Frontier Science & Technology Research Foundation, Inc. (2015); National Cancer Institute (1999–2013); Pediatrics and Genetics (2007); Texas Children's Hospital (2018); Children's Hospital & Medical Center (2011–2014); Johns Hopkins Hospital (2002); Le Bonheur Children's Hospital (1990–1992); OU Health (2011); Indiana University School of Medicine (1999); University of Oklahoma Health Sciences Center (2002–2023); The Ohio State University (2000–2013); Tianjin Medical University (2024); University of Nebraska Medical Center (1999–2014); Virginia Commonwealth University Medical Center (1992); University of Missouri (2002–2011); The University of Texas Southwestern Medical Center (2013–2015); University of Oklahoma (2008–2013); Stanford University (2010); Icahn School of Medicine at Mount Sinai (1982)

81 h-index 461 pubs 21,118 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

David M. Parham has a research focus on rhabdomyosarcomas and related sarcomas, particularly as they affect children and adolescents. His work has involved classifying these tumors and investigating prognostic factors that influence clinical outcomes, as demonstrated in his publications related to the Intergroup Rhabdomyosarcoma Study IV. He has also examined methods for detecting multidrug resistance in tumors and has been involved in studies comparing different chemotherapy regimens for intermediate-risk rhabdomyosarcoma, such as the Children's Oncology Group Study D9803.

Parham's research extends to the molecular basis of rhabdomyosarcoma classification and the immunohistochemical detection of specific proteins like FLI-1. His publications include analyses of cases studied with immunohistochemistry or electron microscopy, contributing to a deeper understanding of tumor pathology. His scholarship metrics include an h-index of 81, over 460 publications, and more than 21,000 citations, designating him as a highly cited researcher.

Metrics

h-index: 81
Publications: 461
Citations: 21,118

Selected Publications

Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution (2025)

DOI OpenAlex

View all publications on OpenAlex →